BWXT Medical Expands Collaboration with Fusion Pharmaceuticals Through Strengthened Actinium Supply and Access to Generator Technology
16 November 2023
(OTTAWA, Ontario – November 16, 2023) – BWXT Medical Ltd. and Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today announced that the companies have entered into an agreement for the supply of generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials.
BWXT Names Mike Boorstein as New General Manager for Euclid Manufacturing Facility
09 November 2023
(EUCLID, Ohio – November 9, 2023) – BWX Technologies, Inc. (NYSE: BWXT) has appointed Mike Boorstein as the new general manager for its Nuclear Operations Group-Euclid manufacturing facility.
BWXT Selected as Nuclear Fuel and Component Manufacturer for Air Force Research Laboratory’s JETSON Program
08 November 2023
BWX Technologies, Inc. announced that it has been selected as the nuclear fuel and components manufacturer for the Air Force Research Laboratory’s Joint Emergent Technology Supplying On-Orbit Nuclear (JETSON) high power mission application program
BWX Technologies Reports Third Quarter 2023 Results
01 November 2023